Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

6,123 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The endothelin axis: emerging role in cancer.
Nelson J, Bagnato A, Battistini B, Nisen P. Nelson J, et al. Nat Rev Cancer. 2003 Feb;3(2):110-6. doi: 10.1038/nrc990. Nat Rev Cancer. 2003. PMID: 12563310 Review.
Nonandrogenic mediators of prostatic growth.
Konety BR, Nelson JB. Konety BR, et al. Hematol Oncol Clin North Am. 2001 Jun;15(3):459-76. doi: 10.1016/s0889-8588(05)70226-4. Hematol Oncol Clin North Am. 2001. PMID: 11525291 Review.
The treatment of prostate cancer: an overview of current options.
Pirtskhalaishvili G, Hrebinko RL, Nelson JB. Pirtskhalaishvili G, et al. Cancer Pract. 2001 Nov-Dec;9(6):295-306. doi: 10.1046/j.1523-5394.2001.96009.x. Cancer Pract. 2001. PMID: 11879332 Review.
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ. Carducci MA, et al. J Clin Oncol. 2002 Apr 15;20(8):2171-80. doi: 10.1200/JCO.2002.08.028. J Clin Oncol. 2002. PMID: 11956279 Clinical Trial.
Endothelin-1 as a target for therapeutic intervention in prostate cancer.
Kopetz ES, Nelson JB, Carducci MA. Kopetz ES, et al. Invest New Drugs. 2002 May;20(2):173-82. doi: 10.1023/a:1015630513908. Invest New Drugs. 2002. PMID: 12099577 Review.
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA. Nelson JB, et al. J Urol. 2003 Mar;169(3):1143-9. doi: 10.1097/01.ju.0000042162.08938.27. J Urol. 2003. PMID: 12576870 Clinical Trial.
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Carducci MA, et al. J Clin Oncol. 2003 Feb 15;21(4):679-89. doi: 10.1200/JCO.2003.04.176. J Clin Oncol. 2003. PMID: 12586806 Clinical Trial.
Endothelin inhibition: novel therapy for prostate cancer.
Nelson JB. Nelson JB. J Urol. 2003 Dec;170(6 Pt 2):S65-7; discussion S67-8. doi: 10.1097/01.ju.0000096372.07687.86. J Urol. 2003. PMID: 14610413 Review.
Prostate cancer: radical prostatectomy.
Nelson JB, Lepor H. Nelson JB, et al. Urol Clin North Am. 2003 Nov;30(4):703-23, viii. doi: 10.1016/s0094-0143(03)00049-1. Urol Clin North Am. 2003. PMID: 14680309 Review.
6,123 results
Jump to page
Feedback